MMEDF - The Chopra Foundation and MindMed Enter Into Letter of Intent to Partner on the Future of Psychedelic Medicines & Mental Wellbeing
NEW YORK, May 18, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED) (OTC:MMEDF)(DE: BGHM) ("MindMed" or the "Company"), a leading clinical-stage psychedelic medicine company, today announced it has entered into a letter of intent to partner with The Chopra Foundation to educate and build public awareness around the use of psychedelic medicines to treat mental illness, remove outdated stigmas, and ultimately research mental wellbeing approaches that can be used in psychedelic related psychotherapy.
Deepak Chopra pictured with MindMed CEO, JR Rahn during MindMed's Nasdaq ListingThe two organizations plan to design and conduct research together ...
Get early insight on hidden secret gems on StockStreetNews . Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here .
All content provided by StockStreetNews is subject to our Terms Of Use and Disclaimer .
For further details see:
The Chopra Foundation and MindMed Enter Into Letter of Intent to Partner on the Future of Psychedelic Medicines & Mental Wellbeing